Chemistry:Albendazole

From HandWiki
Short description: Chemical compound
Albendazole
Albendazole.svg
Albendazole-from-xtal-2007-3D-balls.png
Clinical data
Trade namesAlbenza, Valbazen, Zentel, others
AHFS/Drugs.comMonograph
MedlinePlusa610019
License data
Pregnancy
category
  • AU: D
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only (for humans; veterinary suspension and paste are both OTC)[1]
Pharmacokinetic data
Bioavailability<5%[2]
Protein binding70%[2]
MetabolismHepatic[2]
Elimination half-life8-12 hours[2]
ExcretionBile (humans)
Urine (ruminants)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
Chemical and physical data
FormulaC12H15N3O2S
Molar mass265.33 g·mol−1
3D model (JSmol)
Melting point208 to 210 °C (406 to 410 °F)
  (verify)

Albendazole is a broad-spectrum anthelmintic and antiprotozoal agent of the benzimidazole type.[3] It is used for the treatment of a variety of intestinal parasite infections, including ascariasis, pinworm infection, hookworm infection, trichuriasis, strongyloidiasis, taeniasis, clonorchiasis, opisthorchiasis, cutaneous larva migrans, giardiasis, and gnathostomiasis, among other diseases.[3]

Common side effects include nausea, abdominal pain, and headache.[3] Rare but potentially serious side effects include bone marrow suppression which usually improves on discontinuing the medication. Liver inflammation has been reported and those with prior liver problems are at greater risk.[3] It is pregnancy category D in Australia, meaning it may cause harm if taken by pregnant women.[3][4]

Albendazole was developed in 1975.[5] It is on the World Health Organization's List of Essential Medicines.[6]

Medical uses

Albendazole is an effective treatment for:

Though albendazole is effective in treating many diseases, it is only FDA-approved for treating hydatid disease caused by dog tapeworm larvae and neurocysticercosis caused by pork tapeworm larvae.[20]

Pregnancy

Albendazole is a pregnancy class D drug in Australia. It is contraindicated in the first trimester of pregnancy, and should be avoided up to one month before conception. While studies in pregnant rats and rabbits have shown albendazole to be teratogenic,[21][22] albendazole has been found to be safe in humans during the second and third trimesters.[23][24] It can, however, possibly cause infantile eczema when given during pregnancy.[25]

In pregnant dogs, albendazole use has led to puppies with reduced weight and with cleft palates. Birds have lower rates of laying eggs and hatching when given albendazole.[26]

Albendazole sulfoxide is secreted into breast milk at around 1.5% of the maternal dose, though oral absorption is poor enough that it is unlikely to affect nursing infants.[21][27]

Contraindications

Hypersensitivity to the benzimidazole class of compounds contraindicates its use.[13]

Side effects

Close-up of a pork tapeworm cyst. Destruction of these cysts can cause inflammation.

The most common side effects of albendazole are experienced by over 10% of people and include headache and abnormal liver function.[2] Elevation of liver enzymes occurs in 16% of patients receiving treatment specifically for hydatid disease and goes away when treatment ends.[9][28] Liver enzymes usually increase to two to four times the normal levels (a mild to moderate increase).[29] An estimated 1–10% of people experience abdominal pain, nausea or vomiting, dizziness or vertigo, increased intracranial pressure, meningeal signs, temporary hair loss, and fever. The headache, nausea, and vomiting are thought to be caused by the sudden destruction of cysticerci (tapeworm larvae), which causes acute inflammation.[30] Fewer than 1% of people get hypersensitivity reactions such as rashes and hives, leukopenias (drop in white blood cell levels) such as agranulocytosis and granulocytopenia, thrombocytopenia (reduced platelet count), pancytopenia (drop in white blood cells, red blood cells, and platelets), hepatitis, acute liver failure, acute kidney injury, irreversible bone marrow suppression, and aplastic anemia.[2][31]

Side effects can be different when treating for hydatid disease versus neurocysticercosis: for example, those being treated for the former are more likely to experience elevated liver enzymes and abdominal pain, while those being treated for the latter are more likely to experience headache.[28] Treating hydatid disease can also unmask undiagnosed neurocysticercosis.[28] People receiving albendazole for the treatment of neurocysticercosis can have neurological side effects such as seizures, increased intracranial pressure, and focal signs caused by the inflammatory reaction that occurs when parasites in the brain are killed. Steroids and anticonvulsants are often given with albendazole when treating neurocysticercosis to avoid these effects.[28] Those being treated for retinal neurocysticercosis can face retinal damage if they are not first checked for ocular cysticeri, since changes to existing lesions in the eye by albendazole can cause permanent blindness.[9]

Overdose

Because of its low solubility, albendazole often cannot be absorbed in high enough quantities to be toxic.[30] The oral LD50 of albendazole in rats was found to be 2,500 mg/kg.[22] It takes 20 times the normal dose to kill a sheep, and 30 times the normal dose to kill cattle.[1] Overdose affects the liver, testicles, and GI tract the most. It can manifest with lethargy, loss of appetite, vomiting, diarrhea, intestinal cramps, dizziness, convulsions, and sleepiness. There is no specified antidote.[26]

Interactions

The antiepileptics carbamazepine, phenytoin, and phenobarbital lower the plasma concentration and half-life of albendazole sulfoxide's R(+) enantiomer.[32]

Antiepileptics and pharmacokinetics
of albendazole sulfoxide[17]
Drug Change in AUC Change in Cmax
Carbamazepine 49% decrease 50–63% decrease
Phenobarbitol 61% decrease 50–63% decrease
Phenytoin 66% decrease 50–63% decrease

The antacid cimetidine heightens serum albendazole concentrations, increases the half-life of albendazole, and doubles albendazole sulfoxide levels in bile.[33][28] It was originally thought to work by increasing albendazole bioavailability directly; however, it is now known that cimetidine inhibits the breakdown of albendazole sulfoxide by interfering with CYP3A4.[12] The half-life of albendazole sulfoxide thus increases from 7.4 hours to 19 hours.[34] This might be a helpful interaction on more severe cases, because it boosts the potency of albendazole.[35] Paradoxically, cimetidine also inhibits the absorption of albendazole by reducing gastric acidity.[34]

Several other interactions exist. Corticosteroids increase the steady-state plasma concentration of albendazole sulfoxide;[9] dexamethasone, for example, can increase the concentration by 56% by inhibiting the elimination of albendazole sulfoxide.[28][30] The anti-parasitic praziquantel increases the maximum plasma concentration of albendazole sulfoxide by 50%,[28] and the anti-parasitic levamisole increases the AUC (total drug exposure) by 75%.[17] Grapefruit inhibits the metabolism of albendazole within the intestinal mucosa. Finally, long-term administration of the antiretroviral ritonavir, which works as a CYP3A4 inhibitor, decreases the maximum concentration of albendazole in the plasma as well as the AUC.[34]

Pharmacology

A microtubule is composed of polymers of α- and β-tubulin.

Mechanism of action

As a vermicide, albendazole causes degenerative alterations in the intestinal cells of the worm by binding to the colchicine-sensitive site of β-tubulin, thus inhibiting its polymerization or assembly into microtubules (it binds much better to the β-tubulin of parasites than that of mammals).[3][28] Albendazole leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Albendazole also prevents the formation of spindle fibers needed for cell division, which in turn blocks egg production and development; existing eggs are prevented from hatching.[12][36] Cell motility, maintenance of cell shape, and intracellular transport are also disrupted.[37] At higher concentrations, it disrupts the helminths' metabolic pathways by inhibiting metabolic enzymes such as malate dehydrogenase and fumarate reductase, with inhibition of the latter leading to less energy produced by the Krebs cycle.[1][26][38] Due to diminished ATP production, the parasite is immobilized and eventually dies.

Some parasites have evolved some resistance to albendazole by having a different set of acids constituting β-tubulin, decreasing the binding affinity of albendazole.[28] Some parasites (especially filarial nematodes) live in symbiosis with Wolbachia, a type of intracellular parasite bacteria. In such cases the Wolbachia are necessary to the survival of the parasitic worms.[39] Elimination of Wolbachia from these filarial nematodes generally results in either death or sterility of the host nematode.[40]

Pharmacokinetics

Oral absorption of albendazole varies among species, with 1–5% of the drug being successfully absorbed in humans, 20–30% in rats, and 50% in cattle.[41]

The absorption also largely depends on gastric pH. People have varying gastric pHs on empty stomachs, and thus absorption from one person to another can vary wildly when taken without food.[16] Generally, the absorption in the GI tract is poor due to albendazole's low solubility in water.[3] It is, however, better absorbed than other benzimidazole carbamates.[17] Food stimulates gastric acid secretion, lowering the pH and making albendazole more soluble and thus more easily absorbed.[34] Oral absorption is especially increased with a fatty meal, as albendazole dissolves better in lipids, allowing it to cross the lipid barrier created by the mucus surface of the GI tract.[37][41] To target intestinal parasites, albendazole is taken on an empty stomach to stay within the gut.[42]

Absorption is also affected by how much of the albendazole is degraded within the small intestine by metabolic enzymes in the villi.[16]

General metabolism of albendazole and its sulfoxides.

The pharmacokinetics of albendazole differ slightly between men and women: women have a lower oral clearance and volume of distribution, while men have a lower serum peak concentration.[34]

Albendazole undergoes very fast first-pass metabolism in all species, such that the unchanged drug is undetectable in plasma.[41] Most of it is oxidized into albendazole sulfoxide (also known as ricobendazole and albendazole oxide[22][43]) in the liver by cytochrome P450 oxidases (CYPs) and a flavin-containing monooxygenase (FMO),[44] which was discovered later.[45] In humans, the cytochrome P450 oxidases are thought to include CYP3A4[46] and CYP1A1,[41] while those in the rats are thought to be CYP2C6 and CYP2A1.[47]

Oxidation to albendazole sulfoxide by FMO produces R(+) enantiomers, while oxidation the cytochromes and by some enzymes in the gut epithelium produce S(-). Different species produce the R(+) and S(-) enantiomers in different quantities; humans, dogs, and most other species[47] produce the R(+) enantiomer more (with the human AUC ratio being 80:20).[30][34][41] Compared to the S(-) enantiomer, the R(+) has greater pharmacological activity, lasts longer in the bloodstream, is found in higher concentrations in the infected host tissues, and is found in higher concentrations within the parasites themselves.[47][37] Some albendazole is also converted to hydroxyalbendazole, mainly by CYP2J2.[25][48]

For systemic parasites, albendazole acts as a prodrug, while albendazole sulfoxide reaches systemic circulation and acts as the real antihelminthic.[12] Albendazole sulfoxide is able to cross the blood–brain barrier and enter the cerebrospinal fluid at 43% of plasma concentrations; its ability to enter the central nervous system allows it to treat neurocysticercosis.[34]

Albendazole sulfoxide is converted to the inactive albendazole sulfone by cytochrome P450 oxidases, thought to include CYP3A4[34] or CYP2C.[12] Other inactive metabolites include: 2-aminosulfone, ω-hydroxysulfone, and β-hydroxysulfone.[44][30] The major final metabolites that are excreted by humans are:[12]

  • methyl [5-(propylsulfonyl-1H-benzimidazol-2-yl)] carbamate,
  • methyl [6-hydroxy 5-(n-propylsulfonyl)-1H-benzimidazole-2-yl)] carbamate,
  • methyl [5-(n-propylsulfinyl)-1H-benzimidazole-2-yl)] carbamate,
  • 5-(n-propylsulfonyl)-1H-benzimidazole-2-yl amine, and
  • 5-(n-propysulfinyl)-1H-benzimidazole-2-yl amine.

There are also some minor hydroxylated sulfated or glucuronidated derivatives.[12] No unchanged albendazole is excreted, as it is metabolized too quickly.[2]

In humans, the metabolites are excreted mostly in bile, with only a small amount being excreted in urine (less than 1%) and feces.[2][12] In ruminants, 60–70% of the metabolites are excreted in urine.[26]

Like all benzimidazoles, albendazole has no residual effect, and thus protects poorly against reinfestations.[22]

History

Albendazole, patented in 1975, was invented by Robert J. Gyurik and Vassilios J. Theodorides and assigned to SmithKline Corporation.[49][50] It was introduced in 1977 as an antihelminthic for sheep in Australia, and was registered for human use in 1982.[9][12]

Society and culture

Discarded bottles of albendazole distributed in Africa

Brand names

Brand names include: Albenza,[28] Alworm, Andazol, Eskazole, Noworm, Zentel, Alben-G, ABZ, Cidazole, Wormnil etc.

Economics

The pharmaceutical company Amedra increased the price after purchasing the rights to the drug, instead of lowering it as generics are predicted to do, drawing criticism from patients' rights advocates.[51]

In 2013, GlaxoSmithKline donated 763 million albendazole tablets for the treatment and prevention of parasitic infections in developing countries, bringing the total to over 4 billion tablets donated since 1998.[52]

Research

Albendazole and related compounds or metabolites like albendazole sulfone (ALB-SO2) exhibit antibacterial effects via an unknown, possibly FtsZ-related, mechanism. It inhibits division of Wolbachia and Mycobacterium tuberculosis, turning them into a long "filament" shape as they grow and fail to divide. Since Brugia malayi relies on symbiotic Wolbachia, this would mean that albendazole is targeting both the worm and its essential symbioant.[53]

Veterinary use

Albendazole is mainly used in cattle and sheep, but has found some use in cats and dogs as well;[23] it is also used in ratite birds for flagellate parasites and tapeworms. It is also used off-label to treat endoparasites in goats and pigs.[1]

Albendazole use in animals[1][23][54][55][56]
Cattle Sheep Others
Platyhelminthes (flatworms)
Trematodes
Dicrocoelium (liver flukes) D. dendriticum (lancet liver fluke)[57] D. dendriticum[58]
Fasciola (liver flukes) F. hepatica F. hepatica For F. hepatica and F. gigantica in people[3]
Fascioloides (liver flukes) F. magna[57] F. magna Also for F. magna in South American camelids (ex. llama and alpaca)[58]
Paragonimus (lung flukes) For P. kellicotti in cats and dogs[58]
Platynosomum For Platynosomum infections in cats
Opisthorchiidae For Opisthorchiidae infections in cats
Cestodes (tapeworms)
Echinococcus For Echinococcus cysts in horses and humans[58][3]
Moniezia M. expansa
M. benedini
M. expansa
 
Taenia T. saginata larvae For T. saginata, T. solium, and T. crassiceps in humans[7][8] and Taenia infections in dogs[59]
Thysanosoma T. actinoides
Nematodes (roundworms)
Ancylostoma For Ancylostoma infections in dogs, cats, and humans[58][3]
Bunostomum B. phlebotomum
Capillaria For causative agents of various forms of capillariasis in cats and dogs (including C. philippinensis, C. hepatica, C. aerophila, and C. plica) and intestinal capillariasis (C. philippinensis) in humans.
Chabertia C. ovina
Cooperia C. oncophora
C. punctata
C. oncophora
 
Dictyocaulus (lungworm) D. viviparus D. filaria For D. amfieldi infections in horses
Filaroides (lungworm) For F. hirthi and F. osleri in dogs
Haemonchus H. contortus
H. placei
H. contortus
 
Marshallagia M. marshalli
Metastrongylus For M. apri in swine
Nematodirus N. spathiger
N. helvetianus
N. spathiger
N. filicollis
Parascaris For P. equorum in horses[55]
Ostertagia O. ostertagi O. circumcincta For O. bifurcum in humans
Oesophagostomum O. radiatum O. columbianum
Strongyloides For S. stercoralis in dogs and humans[3][58]
Strongylus For S. equinus in horses[58]
Toxocara For T. canis infections in dogs[58] and toxocariasis in humans (caused by T. canis and T. cati)
Trichostrongylus T. axei
T. colubriformis
T. axei
T. colubriformis
For any Trichostrongylus infection in humans
Trichuris (whipworm) Most species, but those usually found in cattle are:[60]
T. discolor
T. globulosa
T. ovis
Most species, but those usually found in sheep are:[60]
T. discolor
T. globulosa
T. ovis
Albendazole is also used for Trichuris infections in humans (usually T. trichiura, causative agent of trichuriasis), dogs (usually T. vulpis and T. campanula), cats (usually T. serrata and T. campanula), pigs (usually T. suis), and other ruminants (same species as those found in cattle and sheep).[60]
Other
Encephalitozoon For E. cuniculi infections (microsporidiosis) in humans and rabbits
Giardia G. lamblia (causative agent of giardiasis) Also treats giardiasis in humans, dogs, and small mammals
Leishmania Treats leishmaniasis, caused by various species of Leishmania, in dogs

Albendazole has been used as an antihelminthic and for control of flukes in a variety of animal species, including cattle, sheep, goats, swine, camels, dogs, cats, elephants, poultry, and others.[26][61] Side effects include anorexia in dogs and lethargy, depression, and anorexia in cats,[1] with more than 10% of dogs and cats having anorexia.[27] Of dogs and cats, 1–10% experience elevated liver enzymes, nausea, vomiting, and diarrhea. Less than 1% experience neutropenia or aplastic anemia, though these require a use of at least 5 days.[27] While it is also associated with bone marrow suppression and toxicity in cats and dogs at high doses, albendazole has a higher margin of safety in other species.[23][54] Thus, it is usually only prescribed in cats and dogs when an infection is present that is resistant to the commonly prescribed metronidazole and fenbendazole.[62]

It is extensively used for ruminant livestock in Latin America.[22] It is marketed for this purpose by Zoetis (formerly Pfizer Animal Health) in numerous countries (including the United States and Canada) as Valbazen in oral suspension and paste formulations;[1][23] by Interchemie in the Netherlands and elsewhere as Albenol-100; by Channelle Animal Health Ltd. in the United Kingdom as Albex; and by Ravensdown in New Zealand (as Albendazole). Although most formulations are administered orally, Ricomax (ricobendazole, or albendazole sulfoxide) is administered by subcutaneous injection.[citation needed]

Albendazole has greater bioavailability in ruminants: some albendazole sulfoxide, when released back into the rumen, is reduced to albendazole by the resident microbiota, with a preference of the (+) enantiomer being the substrate.[47][37] Cats and dogs, having no rumen reservoir, sometimes need higher or more frequent doses as compared to ruminants. In dogs, albendazole sulfoxide is detectable in the plasma for less than 12 hours, but in sheep and goats, it remains at measurable levels for around three days.[26]

Meat

The limitations in early pregnancy are due to a limited period during which teratogenic effects may occur. Summarized research data relating to the durations of these preslaughter and early pregnancy periods when albendazole should not be administered are found in US FDA NADA 110-048 (cattle) and 140-934 (sheep). Some data and inferences regarding goats are found in US FDA Supplemental NADA 110-048 (approved January 24, 2008).

Maximum residue limits (MRLs) for albendazole in food, adopted by the FAO/WHO Codex Alimentarius in 1993, are 5000, 5000, 100, and 100 micrograms per kilogram of body weight (μg/kg) for kidney, liver, fat, and muscle, respectively, and 100 μg/L for milk. For analysis purposes, MRLs of various nations may pertain to concentration of a marker substance which has been correlated with concentrations of the administered substance and its metabolized products. For example, in Canada, the marker substance specified by Health Canada is albendazole-2-aminosulfone, for which the MRL in liver of cattle is 200 μg/kg.

There is a 27-day cattle withdrawal time for meat.[23]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Albendazole". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. 2011. pp. 19–21. ISBN 978-0-470-95964-0. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "Albenza, (albendazole) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. http://reference.medscape.com/drug/albenza-albendazole-342648#showall. 
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 "Albendazole". The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/albendazole.html. 
  4. Australian Government (March 3, 2014). "Prescribing medicines in pregnancy database". http://www.tga.gov.au/hp/medicines-pregnancy.htm. 
  5. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. 2014. p. 64. ISBN 9781118819593. https://books.google.com/books?id=VOLhBQAAQBAJ&pg=PA64. 
  6. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02. 
  7. 7.0 7.1 7.2 7.3 7.4 Essentials of Medical Pharmacology. JP Medical Ltd. September 30, 2013. p. 850. ISBN 978-93-5025-937-5. https://books.google.com/books?id=FfG8AQAAQBAJ&pg=PA850. 
  8. 8.0 8.1 8.2 8.3 8.4 Comprehensive Dermatologic Drug Therapy E-Book. Elsevier Health Sciences. October 18, 2012. p. 137. ISBN 978-1-4557-3801-4. https://books.google.com/books?id=Tqpsm5WKKlcC&pg=PA137. 
  9. 9.0 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice. Lippincott Williams & Wilkins. 2010. pp. 470–472. ISBN 978-0-7817-9538-8. https://books.google.com/books?id=1e2-yggGeUIC&pg=PA470. 
  10. 10.0 10.1 "Helminths: Cestode (tapeworm) infection: Albendazole". WHO. 1995. http://apps.who.int/medicinedocs/en/d/Jh2922e/3.1.1.html. 
  11. "Albendazole for the treatment of echinococcosis". Fundamental & Clinical Pharmacology 17 (2): 205–212. April 2003. doi:10.1046/j.1472-8206.2003.00171.x. PMID 12667231. 
  12. 12.00 12.01 12.02 12.03 12.04 12.05 12.06 12.07 12.08 12.09 12.10 12.11 "Albendazole". Logan Turner's Diseases of the Nose, Throat and Ear (10th ed.). CRC Press. December 30, 1987. pp. 2227–2239. ISBN 978-0-340-92767-0. https://books.google.com/books?id=2-nwinRKtBQC&pg=PA2227. 
  13. 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 "Helminths: Intestinal nematode infection: Albendazole". WHO. 1995. http://apps.who.int/medicinedocs/en/d/Jh2922e/3.2.1.html. 
  14. 14.0 14.1 14.2 14.3 14.4 Infectious Diseases of the Female Genital Tract. Lippincott Williams & Wilkins. 2009. pp. 379, 382–383. ISBN 978-0-7817-7815-2. https://books.google.com/books?id=wuR_ngItU5oC&pg=PA379. 
  15. "Quick thinking saves a life". 2021. https://abpharmacy.ca/articles/quick-thinking-saves-life. 
  16. 16.0 16.1 16.2 Update Gastroenterology 2004: New Developments in the Management of Benign Gastrointestinal Disorders. John Libbey Eurotext. 2004. pp. 144–145. ISBN 978-2-7420-0538-3. https://books.google.com/books?id=FfyJeSjyo-IC&pg=PA144. 
  17. 17.0 17.1 17.2 17.3 Antibiotic and Chemotherapy E-Book. Elsevier Health Sciences. November 30, 2010. p. 101. ISBN 978-0-7020-4765-7. https://books.google.com/books?id=DE4Mxc3aesEC&pg=PA101. 
  18. 18.0 18.1 "Drugs: Albendazole". WHO. 1999. http://apps.who.int/medicinedocs/en/d/Js2215e/9.2.html. 
  19. "Myiasis". Clinical Microbiology Reviews 25 (1): 79–105. January 2012. doi:10.1128/CMR.00010-11. PMID 22232372. 
  20. "Albenza New FDA Drug Approval". CenterWatch. http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/126/albenza-albendazole. 
  21. 21.0 21.1 "Albendazole (Albenza) Use During Pregnancy". Drugs.com. https://www.drugs.com/pregnancy/albendazole.html. 
  22. 22.0 22.1 22.2 22.3 22.4 "Ricobendazole = Albendazole Sulfoxide for Veterinary Use on Cattle, Sheep, Goats, Pig Poultry, Dogs and Cats against roundworms, tapeworms and liver flukes". July 26, 2015. http://parasitipedia.net/index.php?option=com_content&view=article&id=2518&Itemid=2791. 
  23. 23.0 23.1 23.2 23.3 23.4 23.5 "Albendazole". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. 2007. pp. 8–9. ISBN 978-1-4160-2888-8. 
  24. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. 2011. p. 31. ISBN 978-1-60831-708-0. https://books.google.com/books?id=OIgTE4aynrMC&pg=PA31. 
  25. 25.0 25.1 "CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems". Antimicrobial Agents and Chemotherapy 57 (11): 5448–5456. November 2013. doi:10.1128/AAC.00843-13. PMID 23959307. PMC 3811268. http://aac.asm.org/content/57/11/5448.full. 
  26. 26.0 26.1 26.2 26.3 26.4 26.5 "Albendazole toxicity, poisoning, intoxication, overdose, antidote: safety summary for veterinary use on dogs, cats, cattle, sheep, goats, swine and poultry". Parasitipedia. http://parasitipedia.net/index.php?option=com_content&view=article&id=2697&Itemid=2960. 
  27. 27.0 27.1 27.2 Drug Therapy for Infectious Diseases of the Dog and Cat. John Wiley & Sons. May 11, 2015. p. 247. ISBN 978-1-118-55747-1. https://books.google.com/books?id=jLM_CQAAQBAJ&pg=PA247. 
  28. 28.0 28.1 28.2 28.3 28.4 28.5 28.6 28.7 28.8 28.9 "ALBENZA- albendazole tablet, film coated (NDC Code(s): 52054-550-22, 52054-550-28)". February 2013. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8941166-b77d-45aa-a6e8-04f1c0afd845. 
  29. Manson's Tropical Diseases E-Book. Elsevier Health Sciences. October 26, 2013. p. 807. ISBN 978-0-7020-5306-1. https://books.google.com/books?id=GTjRAQAAQBAJ&pg=PA807. 
  30. 30.0 30.1 30.2 30.3 30.4 "Pharmacology of Anticysticeral Therapy". Taenia Solium Cysticercosis: From Basic to Clinical Science. CABI. 2002. pp. 368–371. ISBN 978-0-85199-839-8. https://books.google.com/books?id=lCAd10-uTtQC&pg=PA368. 
  31. "Albenza (Albendazole) – Warnings and Precautions". http://www.druglib.com/druginfo/albenza/warnings_precautions/. 
  32. "Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis". Therapeutic Drug Monitoring 24 (3): 338–345. June 2002. doi:10.1097/00007691-200206000-00003. PMID 12021623. https://www.researchgate.net/publication/11349600. 
  33. "Effect of dose increase or cimetidine co-administration on albendazole bioavailability". The American Journal of Tropical Medicine and Hygiene 63 (5–6): 270–273. December 2000. doi:10.4269/ajtmh.2000.63.270. PMID 11421376. [yes|permanent dead link|dead link}}]
  34. 34.0 34.1 34.2 34.3 34.4 34.5 34.6 34.7 Principles and Practice of Infectious Diseases. Elsevier Health Sciences. August 28, 2014. p. 520. ISBN 978-1-4557-4801-3. https://books.google.com/books?id=BseNCgAAQBAJ&pg=PA520. 
  35. "Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis". Annals of Tropical Medicine and Parasitology 88 (1): 49–52. February 1994. doi:10.1080/00034983.1994.11812834. PMID 8192515. 
  36. Infectious Diseases in Immunocompromised Hosts. CRC Press. 1997. p. 695. ISBN 978-0-8493-8553-7. https://books.google.com/books?id=73QOP6Xqh6EC&pg=PA695. 
  37. 37.0 37.1 37.2 37.3 Veterinary Pharmacology and Therapeutics. John Wiley & Sons. March 17, 2009. pp. 1054, 1062. ISBN 978-0-8138-2061-3. https://books.google.com/books?id=ievLulSqwBAC&pg=PA1054. 
  38. Medical Pharmacology and Therapeutics E-Book. Elsevier Health Sciences. June 4, 2017. p. 616. ISBN 978-0-7020-7190-4. https://books.google.com/books?id=6b0tDwAAQBAJ&pg=PA616. 
  39. "The Wolbachia Endosymbionts". Microbiology Spectrum (American Society for Microbiology) 7 (2): 1–15. March 2019. doi:10.1128/microbiolspec.bai-0018-2019. PMID 30953430. 
  40. "Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production". Medical Microbiology and Immunology 192 (4): 211–216. November 2003. doi:10.1007/s00430-002-0174-6. PMID 12684759. 
  41. 41.0 41.1 41.2 41.3 41.4 "Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics". Acta Tropica. Preparing to control Schistosomiasis and Soil-transmitted Helminthiasis in the Twenty-First Century 86 (2–3): 141–159. May 2003. doi:10.1016/S0001-706X(03)00031-7. PMID 12745134. 
  42. Handbook of Drug-Nutrient Interactions. Springer Science & Business Media. March 17, 2010. p. 306. ISBN 978-1-60327-362-6. https://books.google.com/books?id=6MSRviXlDtAC&pg=PA306. 
  43. "Ricobendazole | C12H15N3O3S (CID=83969)". National Center for Biotechnology Information. October 17, 2015. https://pubchem.ncbi.nlm.nih.gov/compound/Ricobendazole. 
  44. 44.0 44.1 "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes". British Journal of Clinical Pharmacology 49 (4): 313–322. April 2000. doi:10.1046/j.1365-2125.2000.00170.x. PMID 10759686. 
  45. "Sulfoxidation of albendazole by a cytochrome P450-independent monooxygenase from rat liver microsomes". Veterinary Research Communications 10 (4): 317–324. July 1986. doi:10.1007/BF02213995. PMID 3739217. 
  46. Biochemical, Physiological, and Molecular Aspects of Human Nutrition - E-Book. Elsevier Health Sciences. August 13, 2013. p. 564. ISBN 978-0-323-26695-6. https://books.google.com/books?id=XVNPAQAAQBAJ&pg=PA564. 
  47. 47.0 47.1 47.2 47.3 "Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: pharmacological implications". Veterinary Journal 181 (3): 241–250. September 2009. doi:10.1016/j.tvjl.2008.11.010. PMID 19124257. 
  48. "Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy". Biochemical Pharmacology 135: 12–21. July 2017. doi:10.1016/j.bcp.2017.02.017. PMID 28237650. https://repository.hkbu.edu.hk/cgi/viewcontent.cgi?article=7373&context=hkbu_staff_publication. Retrieved 2019-09-07. 
  49. Gyurkik, Robert; Theodorides, Vassilios, "Methyl 5-propylthio-2-benzimidazolecarbamate", US patent 003915986, published October 28, 1975, assigned to SmithKline Corporation
  50. Gyurik R, Theodorides V, "Methods and compositions for producing polyphasic parasiticide activity using methyl 5-propylthio-2-benzimidazolecarbamate", US patent 956499, published May 11, 1976
  51. "Generic drug price gouging: How Shkreli and other monopolists cornered the market on essential medications". Slate. 2015-09-23. http://www.slate.com/articles/health_and_science/medical_examiner/2015/09/generic_drug_price_gouging_how_shkreli_and_other_monopolists_cornered_the.html. 
  52. "GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis". Annals of Tropical Medicine and Parasitology 103 (Suppl 1): S11–S15. October 2009. doi:10.1179/000349809X12502035776478. PMID 19843393. 
  53. "A cell-based screen reveals that the albendazole metabolite, albendazole sulfone, targets Wolbachia". PLOS Pathogens 8 (9): e1002922. September 2012. doi:10.1371/journal.ppat.1002922. PMID 23028321. 
  54. 54.0 54.1 Georgis' Parasitology for Veterinarians - E-Book. Elsevier Health Sciences. March 12, 2014. p. 282. ISBN 978-1-4557-3988-2. https://books.google.com/books?id=7CFLBAAAQBAJ&pg=PA282. 
  55. 55.0 55.1 "Albendazole for veterinary use on cattle, sheep, goats, pig poultry, dogs and cats against roundworms, tapeworms and liver flukes". Parasitipedia. February 11, 2017. http://parasitipedia.net/index.php?option=com_content&view=article&id=2513&Itemid=2786. 
  56. "VALBAZEN- albendazole suspension". DailyMed. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94cf5818-f27d-4374-87ad-54a2d9ce6ef1. 
  57. 57.0 57.1 Rebhun's Diseases of Dairy Cattle. Elsevier Health Sciences. 2008. p. 238. ISBN 978-1-4160-3137-6. https://books.google.com/books?id=PbEWJrEtECIC&pg=PA238. 
  58. 58.0 58.1 58.2 58.3 58.4 58.5 58.6 58.7 "Albendazole dose for dogs, cats, horses, cattle, sheep, goats, swine and other domestic animals". Parasitipedia. December 8, 2016. http://parasitipedia.net/index.php?option=com_content&view=article&id=3675&Itemid=4072. 
  59. Clinical Pharmacology. Teton NewMedia. March 2001. pp. 91, 142. ISBN 978-1-893441-37-8. https://books.google.com/books?id=NmR00leAkt8C&pg=PA142. 
  60. 60.0 60.1 60.2 "Trichuris spp., parasitic whipworms of dogs, cats and livestock - cattle, sheep, goats and pigs: Biology, prevention and control". Parasitipedia. December 12, 2016. http://parasitipedia.net/index.php?option=com_content&view=article&id=2601&Itemid=2883. 
  61. Biology, Medicine, and Surgery of Elephants. John Wiley & Sons. October 2, 2006. p. 174. ISBN 978-0-8138-0676-1. https://books.google.com/books?id=oCpiZA61tyQC&pg=PA174. 
  62. Clinical Pharmacology. Teton NewMedia. March 2001. p. 142. ISBN 978-1-893441-37-8. https://books.google.com/books?id=NmR00leAkt8C&pg=PA142. 

External links